ETS variant 5 (<i>ETV5</i>), myocyte enhancer factor 2C and ETS transcription factor (<i>ELK4</i>) were considerably enriched in the significant pathway of 'transcriptional misregulation in cancer'.
These data indicated that in addition to EBNA2, TAF family members and MEF2C are essential for ESE activity, MYC expression, and LCL growth.<b>IMPORTANCE</b> SEs play critical roles in cancer development.
Therefore, MEF2C knockdown inhibited the gefitinib resistance and limited the proliferation of hepatic cancer cells in vitro and in vivo, while overexpression of MEF2C showed opposite effect on cancer cell proliferation.